Injectable Portfolio Growth PCC has actively expanded its injectable portfolio with first-to-market generics and new injections such as Edaravone IV Infusion, Pantoprazole Sodium for Injection, Doxycycline for Injection, and Zinc Sulfate Injection launched between 2023 and 2024, signaling a growth-focused strategy in critical care injectables. This positions PCC as a strong source for hospitals and distributors seeking a broader, future-ready formulary and growth opportunities across the critical care aisle.

Manufacturing Strength Fully owned manufacturing facilities in Bethlehem, PA and Digwal, India along with ready to use formulations indicate reliable supply continuity and faster onboarding for new customers. These capabilities support contract manufacturing, private labeling, or exclusive supply agreements with hospital networks and distributors seeking dependable critical care injectables.

Global Market Reach Global reach across the United States, Europe and more than 100 countries enables PCC to service multinational hospital systems and international distributors, reducing supply risk for global customers and enabling cross border collaborations.

Customer Support Edge PCC emphasizes customer centricity and accessible medical information, including a responsive medical information channel for adverse event reporting. This service orientation can be a differentiator when pursuing contracts with health systems that value strong post sale support and pharmacovigilance.

Growth Momentum With revenue in the 100 to 250 million range, leadership momentum from recent executive appointments and ongoing product launches, PCC presents a stable yet growing supplier profile ideal for long term procurement contracts and strategic partnerships.